Under a tenth of individuals who could benefit from obesity jabs such as Wegovy are able to get them, states the WHO as it issues its first guidance on the medications.
Given more than one billion people worldwide now obese, it is calling for more widespread and fairer access to GLP-1 medication.
Per forecasts, in excess of 2,000,000,000 will be obese by 2030 unless action is taken.
"Our latest guidance acknowledges that obesity is a long-term condition that can be addressed with holistic and continuous care," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and logistical bottlenecks are key hurdles to broad availability to the treatments that can help people shift significant body mass, says the organization.
Weight-Loss Drug Supply Crisis
Even in the current best projected case, the manufacturing of GLP-1 therapies might only reach approximately 100 million people – fewer than 10% of those who need them, as stated by the health organization.
The advice urges governments and firms to expand access, by measures like patent sharing.
Exclusive production rights on semaglutide – the primary ingredient of a leading brand – is scheduled to end in multiple countries in 2026.
The Way Obesity Jabs Operate
These medications imitate a biological compound to delay gastric emptying, curb appetite and boost feelings of fullness so individuals eat less.
Patients usually begin shedding pounds in the initial weeks of starting on the regular doses.
Evidence suggests users may see weight return after a year of stopping the treatment, because their usual hunger come back.
To be overweight or obese elevates your chance for experiencing medical conditions, like type 2 diabetes, cardiovascular issues, brain attack, and some malignancies.
Excess weight affects individuals in every country and was associated with millions of deaths worldwide in 2024, according to the WHO.
